Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis

Liver International

Volumn 28, Issue 6, 2008, Pages 814-820

  Choe, Won Hyeok ^a   Kwon, So Young ^a   Kim, Byung Kook ^a   Ko, Soon Young ^a   Yeon, Jong Eun ^b   Byun, Kwan Soo ^b   Kim, Gyun Hwan ^c   Lee, Chang Hong ^a  

^a Konkuk University Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

Author keywords

Adefovir dipivoxil; Antiviral drug resistance; Chronic hepatitis B; Lamivudine; Liver cirrhosis; Tenofovir disoproxil fumarate

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; CREATININE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MONOTHERAPY; TREATMENT DURATION; VIRUS REPLICATION;

ADENINE; ADULT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 44949154430     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01685.x     Document Type: Article

References (24)

1. Locarnini S, Omata M. Molecular virology of hepatitis B virus and the development of antiviral drug resistance. Liver Int 2006; 26: 11-22.
2. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
3. Liaw Y-F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
4. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-43.
5. Buti M, Elifsiniotis I, Jardi R, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007; 47: 366-72.
6. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
7. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
8. van Bömmel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
9. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
10. Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130: 1144-52.
11. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-95.
12. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
13. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
14. Lai CJ, Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am 2004; 33: 629-54.
15. van Bömmel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-25.
16. Santos SA, Uriel AJ, Park JS, et al. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol 2006; 18: 1247-53.
17. Ratziu V, Thibault V, Benhamou Y, et al. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol 2006; 5: 1-4.
18. Trojan J, Stuermer M, Teuber G, et al. Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: Is tenofovir the answer? Gut 2007; 56: 436-7.
19. Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-62.
20. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
21. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
22. Blaas S, Schneidewind A, Gluck T, et al. Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: A report of two cases. AIDS 2006; 20: 1786-7.
23. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
24. Dore GJ, Guan R, Wasim Jafri SM, et al. Management of chronic hepatitis B in challenging patient populations. Liver Int 2006; 26: 38-46.